Fund overview & performance

Asset class

Portfolio solutions

Based on three-year return


Annualized returns

Between % and %

 


Generations

Fund management

Only available for 75/100 guarantee levels

Guarantee level

Series

Clear all filters

CAN International Concentrated Equity

75/100

February 28, 2025

The Fund seeks to achieve long-term capital appreciation by investing primarily in equity securities of companies in any country outside of Canada and the United States.

Is this fund right for you?

  • You want your money to grow over a longer term.
  • You want to invest in companies outside of Canada and the U.S.
  • You're comfortable with a medium level of risk.

Risk Rating

Risk Rating: Moderate

How is the fund invested? (as of December 31, 2024)

Asset allocation (%)

Name Percent
International Equity 99.4
Cash and Equivalents 0.6

Geographic allocation (%)

Name Percent
United Kingdom 19.8
France 16.2
Japan 15.3
Germany 12.7
Sweden 7.9
India 5.6
Taiwan 5.2
Denmark 4.5
Hong Kong 3.3
Other 9.5

Sector allocation (%)

Name Percent
Industrial Goods 19.4
Financial Services 15.2
Consumer Goods 14.8
Technology 14.0
Healthcare 12.0
Real Estate 9.5
Basic Materials 4.9
Industrial Services 3.6
Consumer Services 3.5
Other 3.1

Growth of $10,000 (since inception)

Data not available based on date of inception

Fund details (as of December 31, 2024)

Top holdings %
Sap SE 6.0
HDFC Bank Ltd - ADR 5.6
Taiwan Semiconductor Manufactrg Co Ltd - ADR 5.2
L'Air Liquide SA 4.9
Novo Nordisk A/S Cl B 4.5
Ferguson PLC 4.2
Hoya Corp 4.0
AstraZeneca PLC 3.6
Schneider Electric SE 3.6
Sony Group Corp 3.6
Total allocation in top holdings 45.2
Portfolio characteristics
Standard deviation 14.2%
Dividend yield 1.8%
Average market cap (million) $245,787.1

Understanding returns

Annual compound returns (%)

1 MO 3 MO YTD 1 YR
{{snapShot.Return1Mth|customNumber:1}}{{snapShot.Return3Mth|customNumber:1}}{{snapShot.ReturnYTD|customNumber:1}}{{snapShot.Return1Yr|customNumber:1}}
3 YR 5 YR 10 YR INCEPTION
{{snapShot.Return3Yr|customNumber:1}}{{snapShot.Return5Yr|customNumber:1}}{{snapShot.Return10Yr|customNumber:1}}{{snapShot.ReturnInception|customNumber:1}}

Calendar year returns (%)

2024 2023 2022 2021
{{snapShot.Return1YrCalendar|customNumber:1}}{{snapShot.Return2YrCalendar|customNumber:1}}{{snapShot.Return3YrCalendar|customNumber:1}}{{snapShot.Return4YrCalendar|customNumber:1}}
2020 2019 2018 2017
{{snapShot.Return5YrCalendar|customNumber:1}}{{snapShot.Return6YrCalendar|customNumber:1}}{{snapShot.Return7YrCalendar|customNumber:1}}{{snapShot.Return8YrCalendar|customNumber:1}}

Range of returns over five years (July 1, 2019 - February 28, 2025)

Best return Best period end date Worst return
Worst period end date
8.6% Sept. 2024 5.9% Dec. 2024
Average return % of periods with positive returns Number of positive periods Number of negative periods
7.5% 100.0% 9 0

Q4 2024 Fund Commentary

Market commentary

Global equity markets declined in December after reaching record highs in November following the U.S. presidential election. Equity markets fell in the U.S., Europe and most countries in Asia. The U.S. Federal Reserve Board lowered the federal funds rate for the third time since September. However, it signalled a more gradual approach to future rate cuts.

Performance

The Fund’s relative exposure to Taiwan Semiconductor Manufacturing Co. Ltd. (TSMC), SAP SE and Sony Group Corp. had the most positive impact on performance. There are concerns about artificial intelligence (AI) spending going into 2026 and the need for graphics processing units to train the most advanced AI models. However, TSMC is still expected to benefit from robust growth beyond next year. The need for AI inference should support the growth of ASIC chips and, eventually, Edge AI.

Relative exposure to Novo Nordisk AS had a negative impact on performance. The company released the results of its long-awaited CagriSema trial at the end of December, which fell short of market expectations. This led to the stock falling by 21% in one day. On closer examination, however, the sub-advisor believes the results showed strong efficacy.

At the sector level, stock selection in information technology had a positive impact on the Fund’s performance. Stock selection in financials and industrials had a negative impact.

From a country perspective, exposure to Taiwan had the most positive impact on performance. Overweight exposure to Denmark was negative, driven by the Fund’s overweight holding in Novo Nordisk AS.

Outlook

The Fund remains invested in a balanced portfolio of companies along different parts of the growth spectrum. The sub-advisor continues to focus on unique growth companies with good cash flows and strong balance sheets. The sub-advisor believes this is a good approach for long-term investing and to manage the current environment.

C WorldWide Asset Management

Contact information

Toll free: 1-888-252-1847

{{ snapShot.FundName.replace("<em>", "").replace("</em>", "") }}
No matching records found.

Summary

For the period {{NAVPSPerformanceSummary.StartDate}} through {{NAVPSPerformanceSummary.EndDate}} with $10,000 CAD investment

Total returns performance

{{NAVPSPerformanceSummary.Growth | customPercentage}}

Last price

{{NAVPSPerformanceSummary.NAVPS | customCurrency}} CAD

as of market close {{NAVPSPerformanceSummary.NAVPSDate}}

Value of $10,000 investment

{{NAVPSPerformanceSummary.GrowthOfTenThousand | customCurrency}} CAD

Export to: